Related Experiment Video
Updated: Mar 26, 2026
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Niemann-Pick disease treatment: a systematic review of clinical trials
Alejandro Santos-Lozano1, Diana Villamandos García1, Fabian Sanchis-Gomar1
11 Research Institute of Hospital 12 de Octubre ("i+12"), Madrid, Spain ; 2 GIDFYS, Department of Health Sciences, European University Miguel de Cervantes, Valladolid, Spain ; 3 Faculty of Health Science, University of León, Ponferrada, Spain ; 4 Department of Physiotherapy and Nursing, University of Zaragoza, Huesca, Spain ; 5 GENUD (Growth, Exercise, Nutrition and Development) Research Group, University of Zaragoza, Zaragoza, Spain ; 6 Translational Research Laboratoy in Neuromuscular Diseases, Neurosciences Department, Germans Trias i Pujol Research Institute and Campus Can Ruti, Autonomous University of Barcelona, Badalona, Spain ; 7 European University, Madrid, Spain.
Abstract:
The aim of this systematic review was to analyse all the published clinical trials assessing treatments for Niemann-Pick (NP) disease. At present there are only trials investigating the treatment of NP disease type C. Furthermore, there is no uniformity among studies in treatment outcomes or in data analysis and presentation of results. Miglustat is able to delay neurodegeneration, with greater benefits in patients with a late onset of the disease and β-cyclodextrin-hydroxypropyl (HBP-CD) can attenuate clinical symptoms. As for cholesterol-lowering drugs, the combination of lovastatin, cholestyramine and nicotinic acid is the most effective one for lowering cholesterolemia. Further research is much needed, and ongoing trials using enzyme replacement therapy might hopefully show promising results in the foreseeable future.
